These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 18447605

  • 1. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [Abstract] [Full Text] [Related]

  • 2. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 3. Vernakalant: pharmacology electrophysiology, safety and efficacy.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD.
    Drugs Today (Barc); 2008 May 22; 44(5):325-9. PubMed ID: 18548135
    [Abstract] [Full Text] [Related]

  • 4. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Expert Opin Investig Drugs; 2009 Dec 22; 18(12):1929-37. PubMed ID: 19938903
    [Abstract] [Full Text] [Related]

  • 5. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA, Lau YC, Lip GY.
    Expert Opin Pharmacother; 2014 Apr 22; 15(6):865-72. PubMed ID: 24617913
    [Abstract] [Full Text] [Related]

  • 6. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 22; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

  • 7. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
    Tian D, Frishman WH.
    Cardiol Rev; 2011 Apr 22; 19(1):41-4. PubMed ID: 21135602
    [Abstract] [Full Text] [Related]

  • 8. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.
    Cardiovasc Ther; 2013 Oct 22; 31(5):e55-62. PubMed ID: 23398692
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y, Dobrev D.
    Vasc Health Risk Manag; 2013 Oct 22; 9():165-75. PubMed ID: 23637539
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J.
    J Clin Pharmacol; 2009 Jan 22; 49(1):17-29. PubMed ID: 18927241
    [Abstract] [Full Text] [Related]

  • 11. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A.
    Expert Rev Cardiovasc Ther; 2014 Sep 22; 12(9):1067-75. PubMed ID: 25096598
    [Abstract] [Full Text] [Related]

  • 12. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 15; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.
    J Pharmacokinet Pharmacodyn; 2011 Oct 15; 38(5):541-62. PubMed ID: 21786177
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T, Lafferty J.
    Ann Noninvasive Electrocardiol; 2018 May 15; 23(3):e12508. PubMed ID: 29105209
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs Aging; 2011 Jun 01; 28(6):501-4. PubMed ID: 21639409
    [Abstract] [Full Text] [Related]

  • 17. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007 Jun 01; 8(4):259-65. PubMed ID: 17596113
    [Abstract] [Full Text] [Related]

  • 18. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P, Gilligan P, Mahon P, Sheahan R.
    Ir J Med Sci; 2017 Nov 01; 186(4):903-908. PubMed ID: 28168639
    [Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL, Townsend RW, Gao Y, Wheeler JJ, Kastrissios H, Keirns J.
    J Clin Pharmacol; 2012 Jul 01; 52(7):1042-53. PubMed ID: 21659624
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.